IRIS
DE PLACIDO, SABINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 18.231
NA - Nord America 15.002
EU - Europa 12.522
SA - Sud America 2.169
AF - Africa 474
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 17
Totale 48.436
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.404
SG - Singapore 8.289
RU - Federazione Russa 5.787
VN - Vietnam 3.519
CN - Cina 3.222
IT - Italia 2.030
BR - Brasile 1.711
HK - Hong Kong 1.537
DE - Germania 936
FR - Francia 684
NL - Olanda 588
FI - Finlandia 575
UA - Ucraina 524
GB - Regno Unito 359
IN - India 345
CA - Canada 334
IE - Irlanda 323
JP - Giappone 278
SE - Svezia 225
AR - Argentina 182
MX - Messico 165
CI - Costa d'Avorio 144
ZA - Sudafrica 130
BD - Bangladesh 126
KR - Corea 114
IQ - Iraq 107
PL - Polonia 98
PH - Filippine 94
TH - Thailandia 86
PK - Pakistan 72
BE - Belgio 70
ID - Indonesia 70
ES - Italia 69
EC - Ecuador 65
AT - Austria 59
CO - Colombia 52
TR - Turchia 47
VE - Venezuela 46
UZ - Uzbekistan 44
TW - Taiwan 43
MA - Marocco 35
CL - Cile 34
PY - Paraguay 34
LT - Lituania 27
CZ - Repubblica Ceca 26
KE - Kenya 26
TN - Tunisia 26
JO - Giordania 25
IR - Iran 22
AE - Emirati Arabi Uniti 21
EG - Egitto 21
SA - Arabia Saudita 19
NP - Nepal 18
DZ - Algeria 16
DK - Danimarca 15
PE - Perù 15
AZ - Azerbaigian 14
IL - Israele 14
MY - Malesia 14
SI - Slovenia 14
UY - Uruguay 14
AU - Australia 13
DO - Repubblica Dominicana 13
KZ - Kazakistan 13
LB - Libano 12
BO - Bolivia 11
ET - Etiopia 11
PS - Palestinian Territory 11
RS - Serbia 11
JM - Giamaica 10
LV - Lettonia 10
BG - Bulgaria 9
BZ - Belize 9
CR - Costa Rica 9
HN - Honduras 9
NG - Nigeria 9
PT - Portogallo 9
EU - Europa 8
TT - Trinidad e Tobago 8
AL - Albania 7
KH - Cambogia 7
MD - Moldavia 7
MK - Macedonia 7
NI - Nicaragua 7
PA - Panama 7
RO - Romania 7
SY - Repubblica araba siriana 7
GE - Georgia 6
GT - Guatemala 6
HR - Croazia 6
NZ - Nuova Zelanda 6
SN - Senegal 6
XK - ???statistics.table.value.countryCode.XK??? 6
BH - Bahrain 5
BS - Bahamas 5
BW - Botswana 5
BY - Bielorussia 5
CH - Svizzera 5
PR - Porto Rico 5
BB - Barbados 4
Totale 48.314
Salva come PNG Salva come JPEG
Città #
Singapore 3.953
San Jose 2.408
Hong Kong 1.467
Moscow 1.409
Chandler 1.279
Ashburn 1.130
Beijing 1.026
Ho Chi Minh City 985
Hanoi 841
Santa Clara 596
Amsterdam 540
Millbury 509
Jacksonville 500
The Dalles 469
Naples 451
Los Angeles 425
Lauterbourg 424
Hefei 402
Princeton 367
Munich 345
Napoli 258
Nanjing 254
Dallas 252
Tokyo 247
Buffalo 206
Wilmington 199
New York 197
Boston 184
Ottawa 153
Da Nang 151
São Paulo 150
Haiphong 145
Redondo Beach 134
Turku 124
Des Moines 119
Orem 98
Frankfurt am Main 90
Nanchang 89
Seattle 89
Warsaw 83
Brooklyn 80
Helsinki 77
Houston 77
London 77
Montreal 75
Mexico City 74
Chicago 67
Lawrence 67
Nuremberg 67
Tianjin 67
Dublin 66
Seoul 66
Milan 64
Rome 62
Shenyang 60
Boardman 56
Cagliari 56
Changsha 56
Hebei 56
Johannesburg 56
Pune 56
Brussels 55
Stockholm 55
Council Bluffs 54
Chennai 53
Dong Ket 52
Woodbridge 51
Biên Hòa 49
Hải Dương 49
Atlanta 48
Denver 48
Rio de Janeiro 46
Baghdad 45
Kochi 45
Toronto 44
Jiaxing 42
Norwalk 42
Phoenix 42
Poplar 42
Falkenstein 41
San Francisco 41
Can Tho 40
Falls Church 39
Bangkok 38
Tashkent 38
Ninh Bình 37
Washington 36
Kunming 33
Mumbai 32
Shanghai 32
Belo Horizonte 31
Manchester 31
Guayaquil 30
Brasília 27
Thái Nguyên 26
Charlotte 24
Curitiba 24
Kronberg 24
Porto Alegre 24
Long Xuyen 23
Totale 25.663
Salva come PNG Salva come JPEG
Nome #
GIM3-FATA first adjuvant trial on all aromatase inhibitors in early breast cancer. Studio di fase III di coonfronto tra anastrazolo, letrozolo ed exemestane e tra strategia sequenziale (2 anni di terapia con tamoxifene seguiti da tre anni di terapia con inibitori delle aromatasi) verso strategia up-front (5 anni di terapia con inibitori delle aromatasi) nel trattamento adiuvante del carcinoma mammario ormono-responsivo 324
Manuale di Oncologia Clinica 233
Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype 203
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 193
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 193
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial 191
Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine 182
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. 177
2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility 177
Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis 177
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. 176
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer 176
Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study 176
A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer. 174
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 171
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience 168
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 166
Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer 164
Machine Learning and Texture Analysis of [18F]FDG PET/CT Images for the Prediction of Distant Metastases in Non-Small-Cell Lung Cancer Patients 163
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 160
Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology? 159
Prevalence of Sarcopenia in Women with Breast Cancer 158
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 158
A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA 158
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 157
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 157
The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug? 156
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients 155
Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer. 154
The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer. 154
Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme? 154
Extraskeletal Ewing's sarcoma of the mediastinum: Case report 153
Adjuvant treatment for locally advanced rectal cancer patients after pre-operative chemoradiotherapy: when, and for whom? 153
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial 152
Concomitant Interferon-alfa and chemotherapy in hepatitis C and colorectal cancer: a case report 152
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 152
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 151
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 151
Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction 151
A third-line sorafenib aftrer sequential therapy with sunitinib and mTOR inhibitors in methastatic renal cell carcinoma 150
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 150
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial 150
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 149
Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma: chemotherapy in malignant gastrointestinal neuroectodermal tumour 148
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 148
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis 148
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 148
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 148
Risk factors for cancer-related venous thromboembolism in ambulatory patients. 147
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 147
Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content. 145
Combination of docetaxel and cetuximab for penile cancer: a case report and literature review 145
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 145
Tumor characteristics and prognosis in familial breast cancer 145
Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide 145
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 144
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study 144
RESULTS OF ADJUVANT TREATMENT IN BREAST CANCER WOMEN AGED MORE THAN 70: ITALIAN COOPERATIVE GROUP EXPERIENCE. 143
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. 143
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 143
Heterogeneity of glycolytic phenotype determined by 18F-FDG PET/CT using coefficient of variation in patients with advanced non-small cell lung cancer 142
Biomarkers in localized prostate cancer 142
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 142
The influence of prednisone on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer 142
. 2009 Apr;20(4):. Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. 141
Modified glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical Cystectomy: A multicenter experience 141
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 141
Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study 141
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. 140
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. 140
Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: A retrospective study 140
Double complete response in MCRC patient 139
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 139
Long-term survival and BRCA status in male breast cancer: A retrospective single-center analysis 139
Body weight and risk of molecular breast cancer subtypes among postmenopausal Mediterranean women 139
It is no longer the time to disregard thyroid metastases from breast cancer: A case report and review of the literature 139
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 139
A comprehensive outlook on inracerebral therapy of malignant gliomas 138
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 138
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 138
Heterogeneity of SSTR2 expression assessed by 68Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors 138
Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. 137
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials 137
Multi-gene panel testing increases germline predisposing mutations' detection in a cohort of breast/ovarian cancer patients from Southern Italy 135
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 135
Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. 135
Efficacy of rituximab in gastric diffuse large B cell Lymphoma patients. 135
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 134
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 134
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings 134
Lack of cumulative toxicity associated with cabazitaxel use in prostate cancer 133
The importance of using strain derived criteria for detection of subclinical cardiotoxicity in breast cancer patients undergoing anthracycline and trastuzumab 133
Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers 132
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. 132
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 132
Management of patients with BRCA1/2-associated breast cancer 131
Mechanisms of lapatinib resistance in HER2-driven breast cancer 131
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 131
Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Ten year results of the Naples (GUN) Study. 130
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype 130
Totale 15.223
Salva come PNG Salva come JPEG
Categoria #
all - tutte 151.365
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 151.365
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021272 0 0 0 0 0 0 0 0 0 33 157 82
2021/20222.383 38 8 23 17 44 74 27 97 317 215 560 963
2022/20233.374 470 224 111 227 377 370 31 299 484 540 184 57
2023/20242.306 71 354 359 178 105 229 28 271 35 63 404 209
2024/202513.005 685 788 59 183 326 562 1.217 819 1.141 1.382 4.775 1.068
2025/202623.404 2.735 1.680 2.511 2.234 4.198 1.137 2.854 1.306 3.239 1.510 0 0
Totale 49.061